This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Feb 28:352:i1196.

doi: 10.1136/bmj.i1196.

Aflibercept is better drug for diabetic macular oedema, study finds

Affiliations

PMID: 26929279
DOI: 10.1136/bmj.i1196

Comment

Aflibercept is better drug for diabetic macular oedema, study finds

Jacqui Wise. BMJ. 2016.

. 2016 Feb 28:352:i1196.

doi: 10.1136/bmj.i1196.

Author

Affiliation

¹ London.

PMID: 26929279
DOI: 10.1136/bmj.i1196

No abstract available

PubMed Disclaimer

Comment on

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Wells JA, et al. Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27. Ophthalmology. 2016. PMID: 26935357 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information